Home » Newsletters » BioWorld Science

BioWorld Science

April 22, 2003

View Archived Issues

High doses of interferon beta-1b effective in early relapsing-remitting MS

Atorvastatin reduces cardiovascular events in hypertensive patients with average cholesterol levels

New data on urokinase in intracerebral hematoma

Protective effects against malaria reported for a novel primaquine analogue

Antitumor acridine derivatives prepared and tested at Servier

Three series of IBAT inhibitors identified by AstraZeneca scientists

Novel glucose-lowering agents in Sankyo research pipeline

GSK-3beta or dual GSK-3beta/CDK5 inhibitors for use in AD and other disorders

BMS researchers present new CRF antagonists with utility in anxiety, depression, etc.

Triapine evaluated clinically in combination with cytarabine for leukemia

Macrocyclic modulators of c-fos expression and their use in cancer therapy

Regenecor established to acquire PPL subsidiary

Genmab reviews developments in 2002

Gastrointestinal effects of the kappa opioid receptor agonist asimadoline

A humanized anti-EGFR monoclonal antibody reported safe in advanced epithelial cancer

Potential use of mozavaptan plus furosemide for treating edema and hyponatremia

Activa Therapy receives humanitarian device exemption for dystonia

Ortho-McNeil to acquire Axert marketing rights

Medarex and Pfizer form antibody development partnership

Praecis submits IND to begin phase I trial of PPI-2458 in NHL

GlaxoSmithKline files IND for topotecan TCS

FDA approves Vigamox

Achillion and Phytobiotech to discover drugs for infectious disease

Merger of Pfizer and Pharmacia expected to result in major synergies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 23, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.